Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-01-11T05:01:10.634Z Has data issue: false hasContentIssue false

Chapter 3.3 - Drug and Physical Treatments of Depression

Published online by Cambridge University Press:  04 April 2024

By
Ryan Williams  and
Anthony Cleare
Edited by
David Kingdon ,
Paul Rowlands  and
George Stein
David Kingdon
Affiliation:
University of Southampton
Paul Rowlands
Affiliation:
Derbyshire Healthcare NHS foundation Trust
George Stein
Affiliation:
Emeritus of the Princess Royal University Hospital
Get access

Summary

Classification of drug treatments for depression is described noting the ambiguities of current terminology and the move towards standardised nomenclature based on pharmacology and mode of action, such as that proposed by the Neuroscience-based Nomenclature group. Antidepressant drugs are described in terms of background, mechanism of action, pharmacokinetics, side effects, interactions, contraindications and toxicity in overdose. Groups include selective serotonin re-uptake inhibitors (SSRI), serotonin and noradrenaline re-uptake inhibitors (SNRI), tricyclics, noradrenergic and specific serotoninergic antidepressants (NaSSA), monoamine oxidase inhibitors (MAOI) and others such as buproprion, agomelatine, reboxetine, trazadone and vortioxetine. Augmentary medications are also described, including antipsychotics, antiepileptics and lithium. Developments with the use of ketamine and other compounds are discussed.

The classification of physical treatments for depression is into neuromodulatory (e.g. electroconvulsive therapy, transcranial magnetic stimulation, deep brain stimulation and phototherapy) and neuroablative techniques (e.g. stereotactic psychosurgery).

Keywords

antidepressantsSSRISNRIMAOINaSSAaugmentationlithiumantiepilepticsketamineECTTMSpsychosurgerytreatment algorithms
Type
Chapter
Information
Seminars in General Adult Psychiatry , pp. 108 - 146
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brausch, J, Connors, K, Brooks, B, et al. Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing. Reviews of Environmental Contamination and Toxicology 2012;218:1–99.Google ScholarPubMed
Zanger, UM, Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 2013;138(1):103–41.CrossRefGoogle ScholarPubMed
Haddad, PM. Do antidepressants cause dependence? Epidemiologia e Psichiatria Sociale 2005;14(2):58–62.CrossRefGoogle ScholarPubMed
Sternbach, H. The serotonin syndrome. American Journal of Psychiatry 1991;148(6):705–13.Google ScholarPubMed
Gebhardt, S, Heinzel-Gutenbrunner, M, König, U. Pain relief in depressive disorders: a meta-analysis of the effects of antidepressants. Journal of Clinical Psychopharmacology 2016;36(6):658–68.CrossRefGoogle ScholarPubMed
MacHado, M, Einarson, TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. Journal of Clinical Pharmacy and Therapeutics 2010;35(2):177–88.CrossRefGoogle ScholarPubMed
Blier, P, Briley, M. The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatric Disease and Treatment 2011;7(Suppl 1):15–20.Google ScholarPubMed
McIntyre, RS, Panjwani, ZD, Nguyen, HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opinion on Drug Metabolism & Toxicology 2008;4(3):281–5.CrossRefGoogle ScholarPubMed
Taylor, D, Lenox-Smith, A, Bradley, A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Therapeutic Advances in Psychopharmacology 2013;3(3):151–61.CrossRefGoogle Scholar
Fischer, M, Unterecker, S, Pfuhlmann, B. Overdose of venlafaxine with mild outcome. Neuroscience and Medicine 2012;2012:327–9.Google Scholar
Taylor, D, Barnes, TRE, Young, AH, et al. The Maudsley Prescribing Guidelines in Psychiatry, 14th ed. Hoboken, NJ: Wiley-Blackwell;2021.CrossRefGoogle Scholar
Gray, SL, Anderson, ML, Dublin, S, et al. Cumulative use of strong anticholinergics and incident dementia. JAMA Internal Medicine 2015;175(3):401–7.Google ScholarPubMed
National Institute for Health and Care Excellence. Interactions | BNF content published by NICE. bnf.nice.org.uk/interaction/.Google Scholar
Gijsman, H, Geddes, J, Rendell, J, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry 2004;161(9):1537–47.CrossRefGoogle ScholarPubMed
Hawton, K, Bergen, H, Simkin, S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. British Journal of Psychiatry 2010;196(5):354–8.CrossRefGoogle ScholarPubMed
Henssler, J, Alexander, D, Schwarzer, G, et al. Combining antidepressants vs antidepressant monotherapy for treatment of patients with acute depression: a systematic review and meta-analysis. JAMA Psychiatry 2022;79(4):300–12.CrossRefGoogle ScholarPubMed
Kessler, D, MacNeill, S, Tallon, D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ 2018;363. DOI:10.1136/BMJ.K4218.Google ScholarPubMed
Fawcett, J, Barkin, RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. Journal of Affective Disorders 1998;51(3):267–85.CrossRefGoogle ScholarPubMed
Silva, J, Mota, J, Azevedo, P. California rocket fuel: and what about being a first line treatment? European Psychiatry 2016;33(Supplement):S551.Google Scholar
Houlihan, DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Annals of Pharmacotherapy 2004;38(3):411–3.CrossRefGoogle ScholarPubMed
White, N, Litovitz, T, Clancy, C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. Journal of Medical Toxicology 2008;4(4):238–50.CrossRefGoogle ScholarPubMed
Maxwell, RA, Eckhardt, SB. Drug Discovery: A Casebook and Analysis. London: Springer Science & Business Media;1990.CrossRefGoogle Scholar
Patnode, CD, Henderson, JT, Coppola, EL, et al. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2021;325(3):280–98.CrossRefGoogle ScholarPubMed
Zimmerman, M, Posternak, M, Attiullah, N, et al. Why isn’t bupropion the most frequently prescribed antidepressant? Journal of Clinical Psychiatry 2005;66(5):603–10.Google ScholarPubMed
Pisani, F, Oteri, G, Costa, C, et al. Effects of psychotropic drugs on seizure threshold. Drug Safety 2002;25(2):91–110.CrossRefGoogle ScholarPubMed
Nelson, JC, Spyker, DA. Morbidity and mortality associated with medications used in the treatment of depression: an analysis of cases reported to U.S. poison control centers, 2000–2014. American Journal of Psychiatry 2017;174(5):438–50.CrossRefGoogle ScholarPubMed
Taylor, D, Sparshatt, A, Varma, S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014;348:g1888. DOI:10.1136/BMJ.G1888.CrossRefGoogle ScholarPubMed
Eyding, D, Lelgemann, M, Grouven, U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737.CrossRefGoogle ScholarPubMed
Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391(10128):1357–66.CrossRefGoogle ScholarPubMed
Stryjer, R, Spivak, B, Strous, RD, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clinical Neuropharmacology 2009;32(2):82–4.CrossRefGoogle ScholarPubMed
Abber, JC, Lue, TF, Luo, JA, et al. Priapism induced by chlorpromazine and trazodone: mechanism of action. Journal of Urology 1987;137(5):1039–42.CrossRefGoogle ScholarPubMed
Battaglia, C, Venturoli, S. Persistent genital arousal disorder and trazodone. Morphometric and vascular modifications of the clitoris. A case report. Journal of Sexual Medicine 2009;6(10):2896–900.CrossRefGoogle ScholarPubMed
Martínez, MA, Ballesteros, S, Sánchez De La Torre, C, et al. Investigation of a fatality due to trazodone poisoning: case report and literature review. Journal of Analytical Toxicology 2005;29(4):262–8.Google ScholarPubMed
Sanchez, C, Asin, KE, Artigas, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology & Therapeutics 2015;145:43–57.CrossRefGoogle ScholarPubMed
Bishop, MM, Fixen, DR, Linnebur, SA, et al. Cognitive effects of vortioxetine in older adults: a systematic review. Therapeutic Advance in Psychopharmacology 2021;11:1–10. DOI: 10.1177/20451253211026796.Google ScholarPubMed
Robertson, MM, Trimble, MR. Major tranquillisers used as antidepressants. A review. Journal of Affective Disorders 1982;4(3):173–93.CrossRefGoogle ScholarPubMed
Spielmans, G, Berman, M, Linardatos, E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10(3):e1001403. DOI: 10.1371/JOURNAL.PMED.1001403.CrossRefGoogle ScholarPubMed
Berman, R, Marcus, R, Swanink, R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2007;68(6):843–53.Google ScholarPubMed
Brunner, E, Tohen, M, Osuntokun, O, Landry, J, Thase, ME. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 2014;39(11):2549–59.CrossRefGoogle ScholarPubMed
Nelson, J, Papakostas, G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry 2009;166(9):980–91.CrossRefGoogle ScholarPubMed
Vieta, E, Bauer, M, Montgomery, S, et al. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. Journal of Affective Disorders 2013;150(2):639–43.CrossRefGoogle ScholarPubMed
Taylor, D, Cornelius, V, Smith, L, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatrica Scandandinavica 2014;130(6):452–69.Google ScholarPubMed
Cade, JFJ. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949;2(1):349–52.CrossRefGoogle ScholarPubMed
Crossley, N, Bauer, M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 2007;68(6):935–40.Google ScholarPubMed
Bauer, M, Adli, M, Ricken, R, et al. Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 2014;28(4):331–42.CrossRefGoogle ScholarPubMed
Birkenhäger, T, van den Broek, W, Moleman, P, et al. Outcome of a 4-step treatment algorithm for depressed inpatients. Journal of Clinical Psychiatry 2006;67(8):1266–71.Google ScholarPubMed
Nierenberg, AA, Fava, M, Trivedi, M, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. American Journal of Psychiatry 2006;163(9):1519–30.CrossRefGoogle Scholar
Bauer, M, Dell’osso, L, Kasper, S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. Journal of Affective Disorders 2013;151(1):209–19.CrossRefGoogle ScholarPubMed
Cipriani, A, Hawton, K, Stockton, S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646. DOI: 10.1136/BMJ.F3646.CrossRefGoogle ScholarPubMed
Tiihonen, J, Tanskanen, A, Hoti, F, et al. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Lancet Psychiatry 2017;4(7):547–53.CrossRefGoogle ScholarPubMed
Böer, U, Cierny, I, Krause, D, et al. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacology 2007;33(10):2407–15.Google ScholarPubMed
Scheuch, K, Höltje, M, Budde, H, et al. Lithium modulates tryptophan hydroxylase 2 gene expression and serotonin release in primary cultures of serotonergic raphe neurons. Brain Research 2010;1307:14–21.CrossRefGoogle ScholarPubMed
Einat, H, Manji, HK. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biological Psychiatry 2006;59(12):1160–71.CrossRefGoogle ScholarPubMed
Gould, T, Picchini, A, Einat, H, et al. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Current Drug Targets 2006;7(11):1399–409.CrossRefGoogle ScholarPubMed
Ghasemi, M, Raza, M, Dehpour, AR. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. Journal of Psychopharmacology (Oxford) 2010;24(4):585–94.Google ScholarPubMed
Malhi, GS, Tanious, M, Das, P, et al. Potential mechanisms of action of lithium in bipolar disorder. CNS Drugs 2013;27(2):135–53.CrossRefGoogle ScholarPubMed
Gong, R, Wang, P, Dworkin, L. What we need to know about the effect of lithium on the kidney. American Journal of Physiology. Renal Physiology 2016;311(6):F1168–71.CrossRefGoogle ScholarPubMed
McKnight, RF, Adida, M, Budge, K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379(9817):721–8.CrossRefGoogle ScholarPubMed
Barbosa, L, Berk, M, Vorster, M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry 2003;64:403–7.Google ScholarPubMed
Schindler, F, Anghelescu, I. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International Clinical Psychopharmacology 2007;22(3):179–82.CrossRefGoogle ScholarPubMed
Alyahya, B, Friesen, M, Nauche, B, et al. Acute lamotrigine overdose: a systematic review of published adult and pediatric cases. Clinical Toxicology (Philadelphia) 2018;56(2):81–9.CrossRefGoogle ScholarPubMed
D’haenen, H, Boer, J den, Willner, P. Biological Psychiatry. Chichester: John Wiley & Sons Ltd; 2002. ndl.ethernet.edu.et/bitstream/123456789/12897/1/Hugo%20D%E2%80%99haenen.pdf.CrossRefGoogle Scholar
Hage, MP, Azar, ST. The link between thyroid function and depression. Journal of Thyroid Research 2012;2012:590648. DOI: 10.1155/2012/590648.CrossRefGoogle ScholarPubMed
Kirkegaard, C, Faber, J. Altered serum levels of thyroxine, triiodothyronines and diiodothyronines in endogenous depression. Acta Endocrinologica 1981;96(2):199–207.Google ScholarPubMed
Aronson, R, Offman, H, Joffe, R, Naylor, C. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Archives of General Psychiatry 1996;53(9):842–8.CrossRefGoogle ScholarPubMed
Nuñez, NA, Joseph, B, Pahwa, M, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. Journal of Affective Disorders 2022;302:385–400.CrossRefGoogle ScholarPubMed
Zhou, X, Ravindran, A v, Qin, B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. Journal of Clinical Psychiatry 2015;76(4):487–98.Google ScholarPubMed
Rosenthal, LJ, Goldner, WS, O’Reardon, JP. T3 augmentation in major depressive disorder: Safety considerations. American Journal of Psychiatry 2011;168(10):1035–40.CrossRefGoogle ScholarPubMed
Trivedi, MH, Fava, M, Wisniewski, SR, et al. Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 2009;354(12):1243–52. dx.doi.org/10.1056/NEJMoa052964.Google Scholar
Appelberg, BG, Syvalahti, EK, Koskinen, TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Journal of Clinical Psychiatry 2001;62(6):448–52.Google ScholarPubMed
Landén, M, Björling, G, Fahlén, T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Journal of Clinical Psychiatry 1998;59(12):664–8.Google ScholarPubMed
Burkhart, KK. Medical Toxicology. Philadelphia: Lippincott Williams & Wilkins; 2004.Google Scholar
Blier, P, Bergeron, R. The use of pindolol to potentiate antidepressant medication. Journal of Clinical Psychiatry 1998;59(Suppl 5):16–23, discussion 24–5.Google ScholarPubMed
Liu, Y, Zhou, X, Zhu, D, et al. Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis. Human Psychopharmacology 2015;30(3):132–42.CrossRefGoogle ScholarPubMed
Segrave, R, Nathan, PJ. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression. Human Psychopharmacology: Clinical and Experimental 2005;20(3):163–74.CrossRefGoogle ScholarPubMed
Celada, P, Bortolozzi, A, Artigas, F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 2013;27(9):703–16.CrossRefGoogle ScholarPubMed
Domino, EF. Taming the ketamine tiger. 1965. Anesthesiology 2010;113(3):678–84.CrossRefGoogle ScholarPubMed
Mion, G. History of anaesthesia: the ketamine story – past, present and future. European Journal of Anaesthesiology 2017;34(9):571–5.CrossRefGoogle ScholarPubMed
Murrough, JW, Iosifescu, D v., Chang, LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry 2013;170(10):1134.CrossRefGoogle ScholarPubMed
Rot, MA het, Zarate, CA, Charney, DS, et al. Ketamine for depression: where do we go from here? Biological Psychiatry 2012;72(7):537–47.Google Scholar
Canuso, CM, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. American Journal of Psychiatry 2019;17(7):55–65. doi.org/10.1176/appi.ajp.2018.17060720.Google ScholarPubMed
Williams, NR, Heifets, BD, Blasey, C, et al. Opioid receptor antagonism attenuates antidepressant effects of ketamine. American Journal of Psychiatry 2018;175(12):1205.CrossRefGoogle ScholarPubMed
Smith, HS. Ketamine-induced urologic insult (KIUI). Pain Physician 2010;13(6):E343–6.Google ScholarPubMed
Morgan, CJA, Curran, HV. Ketamine use: a review. Addiction 2012;107(1):27–38.CrossRefGoogle ScholarPubMed
Andrade, C. Ketamine for depression, 5: potential pharmacokinetic and pharmacodynamic drug interactions. Journal of Clinical Psychiatry 2017;78(7):e858–61.Google ScholarPubMed
Dörks, M, Langner, I, Dittmann, U, et al. Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. European Child & Adolescent Psychiatry 2013;22(80):511–8.CrossRefGoogle ScholarPubMed
Linde, K, Berner, MM, Kriston, L. St John’s Wort for major depression. Cochrane Database of Systematic Reviews 2008;2008(4):CD000448.Google ScholarPubMed
Apaydin, EA, Maher, AR, Shanman, R, et al. A systematic review of St. John’s wort for major depressive disorder. Systematic Reviews 2016;5(1):148.CrossRefGoogle ScholarPubMed
Ng, QX, Venkatanarayanan, N, Ho, CYX. Clinical use of Hypericum perforatum (St John’s wort) in depression: a meta-analysis. Journal of Affective Disorders 2017;210:211–21.CrossRefGoogle ScholarPubMed
Hoban, CL, Byard, RW, Musgrave, IF. A comparison of patterns of spontaneous adverse drug reaction reporting with St. John’s Wort and fluoxetine during the period 2000–2013. Clinical and Experimental Pharmacology and Physiology 2015;42(7):747–51.CrossRefGoogle ScholarPubMed
Karalapillai, DC, Bellomo, R. Convulsions associated with an overdose of St John’s wort. Medical Journal of Australia 2007;186(4):213–4.CrossRefGoogle ScholarPubMed
Young, SN. The effect of raising and lowering tryptophan levels on human mood and social behaviour. Philosophical Transactions of the Royal Society B: Biological Sciences 2013;368(1615):20110375. DOI:10.1098/RSTB.2011.0375.CrossRefGoogle ScholarPubMed
Ravindran, A v., da Silva, TL. Complementary and alternative therapies as add-on to pharmacotherapy for mood and anxiety disorders: a systematic review. Journal of Affective Disorders 2013;150(3):707–19.CrossRefGoogle ScholarPubMed
Shaw, KA, Turner, J, del Mar, C. Tryptophan and 5-Hydroxytryptophan for depression. Cochrane Database of Systematic Reviews 2002;1:CD003198. DOI:10.1002/14651858.cd003198.Google Scholar
Miller, AH, Maletic, V, Raison, CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry 2009;65(9):732–41.CrossRefGoogle ScholarPubMed
Na, KS, Lee, KJ, Lee, JS, et al. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Progress in Neuro-psychopharmacology & Biological Psychiatry 2014;48:79–85.CrossRefGoogle ScholarPubMed
Raison, CL, Rutherford, RE, Woolwine, BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013;70(1):31–41.CrossRefGoogle ScholarPubMed
Husain, MI, Strawbridge, R, Stokes, PRA, et al. Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. Journal of Psychopharmacology 2017;31(9):1137–48.CrossRefGoogle ScholarPubMed
Nettis, MA, Lombardo, G, Hastings, C, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology 2021;46(5):939–48.Google ScholarPubMed
Aizenstein, HJ, Baskys, A, Boldrini, M, et al. Vascular depression consensus report – a critical update. BMC Med 2016;14:1–16.CrossRefGoogle ScholarPubMed
Cipriani, A, Saunders, K, Attenburrow, MJ, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Molecular Psychiatry 2016;21(10):1324–32.CrossRefGoogle ScholarPubMed
Taragano, FE, Bagnatti, P, Allegri, RF. A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of ‘vascular depression’. International Psychogeriatrics 2005;17(3):487–98.CrossRefGoogle ScholarPubMed
Goodnick, PJ. The use of nimodipine in the treatment of mood disorders. Bipolar Disorders 2000;2(3 Pt 1):165–73.CrossRefGoogle ScholarPubMed
Dean, O, Giorlando, F, Berk, M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. Journal of Psychiatry & Neuroscience 2011;36(2):78–86.CrossRefGoogle ScholarPubMed
Bozzatello, P, Brignolo, E, de Grandi, E, et al. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. Journal of Clinical Medicine 2016;5(8):67. DOI:10.3390/JCM5080067.CrossRefGoogle ScholarPubMed
Cuomo, A, Beccarini Crescenzi, B, Bolognesi, S, et al. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Annals of Genera; Psychiatry 2020;19:50. DOI:10.1186/S12991-020-00298-Z.CrossRefGoogle ScholarPubMed
Ravindran, A v., Balneaves, LG, Faulkner, G, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 5. Complementary and alternative medicine treatments. Canadian Journal of Psychiatry 2016;61(9):576–87.CrossRefGoogle Scholar
Akers, BP, Ruiz, JF, Piper, A, et al. A prehistoric mural in Spain depicting neurotropic Psilocybe mushrooms? Economic Botany 2011;65(2):121–8.CrossRefGoogle Scholar
Goldberg, SB, Pace, BT, Nicholas, CR, et al. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Research 2020;284:112749.CrossRefGoogle ScholarPubMed
Rucker, JJ, Young, AH. Psilocybin: from serendipity to credibility? Frontiers in Psychiatry 2021;12:445.CrossRefGoogle ScholarPubMed
Fantegrossi, WE, Murnane, KS, Reissig, CJ. The behavioral pharmacology of hallucinogens. Biochemical Pharmacology 2008;75(1):17–33.CrossRefGoogle ScholarPubMed
Vollenweider, FX, Vollenweider-Scherpenhuyzen, MFI, Bäbler, A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998;9(17):3897–902.CrossRefGoogle Scholar
Kalant, H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ: Canadian Medical Association Journal 2001;165(7):917–28.Google ScholarPubMed
Cerletti, U, Bini, L. L’Elettroshock. Archivio Generale di Neurologia, Psichiatria e Psicoanalisi 1938;19:266–8.Google Scholar
Pagnin, D, de Queiroz, V, Pini, S, et al. Efficacy of ECT in depression: a meta-analytic review. Journal of ECT 2004;20(1):13–20.CrossRefGoogle ScholarPubMed
Geddes, J, Carney, S, Cowen, P, et al. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361(9360):799–808.Google Scholar
Sackeim, HA. Modern electroconvulsive therapy: vastly improved yet greatly underused. JAMA Psychiatry 2017;74(8):779–80.CrossRefGoogle ScholarPubMed
Sackeim, HA, Haskett, RF, Mulsant, BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001;285(10):1299–307.CrossRefGoogle ScholarPubMed
Martínez-Amorós, E, Cardoner, N, Gálvez, V, et al. Can the addition of maintenance electroconvulsive therapy to pharmacotherapy improve relapse prevention in severe major depressive disorder? A randomized controlled trial. Brain Science 2021;11(10):1340. DOI:10.3390/BRAINSCI11101340.CrossRefGoogle ScholarPubMed
Kellner, CH, Jørgensen, MB. Dosing methods in electroconvulsive therapy (ECT): towards the modal ECT technique. Nordic Journal of Psychiatry 2021;76(3):159–61.Google ScholarPubMed
Ferrie, IN, Waite, J. ECT Handbook, 4th ed. Cambridge: Cambridge University Press; 2019.CrossRefGoogle Scholar
Tsoukalas, I. How does ECT work? A new explanatory model and suggestions for non-convulsive applications. Medical Hypotheses 2020;145:110337.CrossRefGoogle Scholar
Jan Shah, A, Wadoo, O, Latoo, J. Electroconvulsive Therapy (ECT): important parameters which influence its effectiveness. British Journal of Medical Practitioners 2013;6:634.Google Scholar
Lisanby, SH, Maddox, JH, Prudic, J, et al. The effects of electroconvulsive therapy on memory of autobiographical and public events. Archives of General Psychiatry 2000;57(6):581–90.CrossRefGoogle ScholarPubMed
Semkovska, M, McLoughlin, DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biological Psychiatry 2010;68(6):568–77.CrossRefGoogle ScholarPubMed
Squire, LR, Slater, PC. Electroconvulsive therapy and complaints of memory dysfunction: a prospective three-year follow-up study. British Journal of Psychiatry 1983;142:1–8.CrossRefGoogle ScholarPubMed
Jolly, A, Singh, S. Does electroconvulsive therapy cause brain damage: An update. Indian J Psychiatry 2020;62(4):339.Google ScholarPubMed
Semkovska, M, McLoughlin, DM. Measuring retrograde autobiographical amnesia following electroconvulsive therapy: historical perspective and current issues. Journal of ECT 2013;29(2):127–33.CrossRefGoogle ScholarPubMed
Duma, A, Maleczek, M, Panjikaran, B, et al. Major adverse cardiac events and mortality associated with electroconvulsive therapy: a systematic review and meta-analysis. Anesthesiology 2019;130(1):83–91.CrossRefGoogle ScholarPubMed
Reed, T, Cohen, KR. Transcranial electrical stimulation (tES) mechanisms and its effects on cortical excitability and connectivity. Journal of Inherited Metabolic Disease 2018;41(6):1123.CrossRefGoogle ScholarPubMed
Horvath, JC, Perez, JM, Forrow, L, et al. Transcranial magnetic stimulation: a historical evaluation and future prognosis of therapeutically relevant ethical concerns. Journal of Medical Ethics 2011;37(3):137–43.CrossRefGoogle ScholarPubMed
Perera, T, George, M, Grammer, G, et al. TMS Therapy for Major Depressive Disorder: Evidence Review and Treatment Recommendations for Clinical Practice. 2015. tmscenterofcolorado.com/wp-content/uploads/2015/09/Clinical-TMS-Society-WhitePaper_2015.pdf.Google Scholar
Berlim, MT, van den Eynde, F, Jeff Daskalakis, Z. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology 2012;38(4):543–51.Google ScholarPubMed
Carpenter, LL, Philip, NS. The future is now? Rapid advances by brain stimulation innovation. American Journal of Psychiatry 2020;177(8):654–6. doi.org/10.1176/appi.ajp.2020.20060844.CrossRefGoogle ScholarPubMed
Cusin, C, Dougherty, DD. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biology of Mood & Anxiety Disorders 2012;2:14.CrossRefGoogle ScholarPubMed
Fitzgerald, PB, Daskalakis, ZJ. Repetitive Transcranial Magnetic Stimulation Treatment for Depressive Disorders: A Practical Guide. London: Springer Science & Business Media; 2013.CrossRefGoogle Scholar
Anderson, RJ, Frye, MA, Abulseoud, OA, et al. Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action. Neuroscience and Biobehavioral Reviews 2012;36(8):1920–33.CrossRefGoogle ScholarPubMed
Dougherty, DD, Rezai, AR, Carpenter, LL, et al. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biological Psychiatry 2015;78(4):240–8.CrossRefGoogle ScholarPubMed
Bergfeld, IO, Mantione, M, Hoogendoorn, MLC, et al. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2016;73(5):456–64.CrossRefGoogle ScholarPubMed
Schlaepfer, TE, Bewernick, BH, Kayser, S, et al. Rapid effects of deep brain stimulation for treatment-resistant major depression. Biological Psychiatry 2013;73(12):1204–12.CrossRefGoogle ScholarPubMed
Elger, G, Hoppe, C, Falkai, P, et al. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Research 2000;42(2–3):203–10.CrossRefGoogle ScholarPubMed
Cimpianu, CL, Strube, W, Falkai, P, et al. Vagus nerve stimulation in psychiatry: a systematic review of the available evidence. Journal of Neural Transmission (Vienna) 2017;124(1):145–58.Google ScholarPubMed
Carreno, FR, Frazer, A. Vagal nerve stimulation for treatment-resistant depression. Neurotherapeutics 2017;14(3):716.CrossRefGoogle ScholarPubMed
Aaronson, ST, Sears, P, Ruvuna, F, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. American Journal of Psychiatry 2017;174(7):640–8.CrossRefGoogle ScholarPubMed
Groves, DA, Brown, VJ. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neuroscience and Biobehavioral Reviews 2005;29(3):493–500.CrossRefGoogle ScholarPubMed
Tuunainen, A, Kripke, DF, Endo, T. Light therapy for non-seasonal depression. Cochrane Database of Systematic Reviews 2004;2004: CD004050.Google ScholarPubMed
Al-Karawi, D, Jubair, L. Bright light therapy for nonseasonal depression: Meta-analysis of clinical trials. Journal of Affective Disorders 2016;198: 64–71.CrossRefGoogle ScholarPubMed
Mårtensson, B, Pettersson, A, Berglund, L, et al. Bright white light therapy in depression: a critical review of the evidence. Journal of Affective Disorders 2015;182:1–7.CrossRefGoogle ScholarPubMed
Oldham, MA, Ciraulo, DA. Bright light therapy for depression: a review of its effects on chronobiology and the autonomic nervous system. Chronobiology International 2014;31(3):305–19.CrossRefGoogle ScholarPubMed
Volpini, M, Giacobbe, P, Cosgrove, GR, et al. The history and future of ablative neurosurgery for major depressive disorder. Stereotactic and Functional Neurosurgery 2017;95(4):216–28.CrossRefGoogle ScholarPubMed
Shields, DC, Asaad, W, Eskandar, EN, et al. Prospective assessment of stereotactic ablative surgery for intractable major depression. Biological Psychiatry 2008;64(6):449–54.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence (NICE). Depression in Adults: Recognition and Management (CG90). 2009.Google Scholar
Cleare, A, Pariante, CM, Young, AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2015;29(5):459–525.CrossRefGoogle ScholarPubMed
Garyfallos, G, Adamopoulou, A, Karastergiou, A, et al. Personality disorders in dysthymia and major depression. Acta Psychiatrica Scandinavica 1999;99(5):332–40.CrossRefGoogle ScholarPubMed
Levkovitz, Y, Tedeschini, E, Papakostas, GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials. Journal of Clinical Psychiatry 2011;72(4):509–14.Google ScholarPubMed
Angst, J, Gamma, A, Bowden, C, et al. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. European Archives of Psychiatry and Clinical Neuroscience 2012;262(1):3–11.CrossRefGoogle Scholar
Verdolini, N, Hidalgo-Mazzei, D, Murru, A, et al. Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines. Acta Psychiatrica Scandinavica 2018;138(3):196–222.CrossRefGoogle ScholarPubMed
Day, E, Shah, R, Taylor, RW, et al. A retrospective examination of care pathways in individuals with treatment-resistant depression. BJPsych Open 2021;7(3):e101. DOI: 10.1192/BJO.2021.59.CrossRefGoogle ScholarPubMed
Stassen, HH, Angst, J, Delini-Stula, A. Delayed onset of action of antidepressant drugs? Survey of recent results. European Psychiatry 1997;12(4):166–76.CrossRefGoogle ScholarPubMed
Posternak, MA, Zimmerman, M. Is there a delay in the antidepressant effect? A meta-analysis. Journal of Clinical Psychiatry 2005;66(2):148–58.Google Scholar
Szegedi, A, Müller, MJ, Anghelescu, I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Journal of Clinical Psychiatry 2003;64(4):413–20.Google ScholarPubMed
Farabaugh, AH, Alpert, J. Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 2000;157(9):1423–8. DOI: 10.1176/appi.ajp.157.9.1423.Google Scholar
Sforzini, L, Worrell, C, Kose, M, et al. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry 2022;27(3):1286–99. DOI: 10.1038/S41380-021-01381-X.CrossRefGoogle ScholarPubMed
Bousman, CA, Arandjelovic, K, Mancuso, SG, et al. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics 2019;20(1):37–47.CrossRefGoogle ScholarPubMed
Reis, M, Aamo, T, Spigset, O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Therapeutic Drug Monitoring 2009;31(1):42–56.CrossRefGoogle Scholar
Xiang, Y-T, Xiao, L, Ungvari, G. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. American Journal of Psychiatry 2015;172(10):1004–13. DOI: 10.1176/appi.ajp.2015.14050652.Google Scholar
Posternak, MA, Zimmerman, M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: Meta-analysis. The British Journal of Psychiatry 2007;190:287–92.CrossRefGoogle ScholarPubMed
Simon, GE, Savarino, J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. American Journal of Psychiatry 2007;164(7):1029–34.CrossRefGoogle ScholarPubMed
Hotopf, M, Hardy, R, Lewis, G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. British Journal of Psychiatry 1997;170:120–7.CrossRefGoogle ScholarPubMed
Sawada, N, Uchida, H, Suzuki, T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 2009;9:1–10.CrossRefGoogle ScholarPubMed
Maidment, R, Livingston, G, Katona, C. ‘Just keep taking the tablets’: adherence to antidepressant treatment in older people in primary care. International Journal of Geriatric Psychiatry 2002;17(8):752–7.CrossRefGoogle ScholarPubMed
Vergouwen, ACM, Bakker, A, Katon, WJ, et al. Improving adherence to antidepressants: a systematic review of interventions. Journal of Clinical Psychiatry 2003;64(12):8795.Google ScholarPubMed
Greist, J, McNamara, RK, Mallinckrodt, CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clinical Therapeutics 2004;26(9):1446–55.CrossRefGoogle ScholarPubMed
Demyttenaere, K, Albert, A, Mesters, P, et al. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? Journal of Clinical Psychiatry 2005;(7):859–63.CrossRefGoogle Scholar
Taylor, MJ, Rudkin, L, Bullemor-Day, P, et al. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews 2013;2013(5):CD0033. DOI:10.1002/14651858.CD003382.PUB3.Google Scholar
Nurnberg, HG, Hensley, PL, Heiman, JR, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300(4):395–404.CrossRefGoogle ScholarPubMed
Stübner, S, Grohmann, R, Greil, W, et al. Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP Multicenter Drug Safety Surveillance Project. International Journal of Neuropsychopharmacology 2018;21(9):814–21.CrossRefGoogle ScholarPubMed
Baldessarini, RJ, Lau, WK, Sim, J, et al. Suicidal risks in reports of long-term treatment trials for major depressive disorder. International Journal of Neuropsychopharmacology 2015;19(3):1–2.Google ScholarPubMed
Moore, TJ, Glenmullen, J, Furberg, CD. Prescription drugs associated with reports of violence towards others. PLoS ONE 2010;5(12):e15337. DOI: 10.1371/JOURNAL.PONE.0015337.CrossRefGoogle ScholarPubMed
Read, J, Gee, A, Diggle, J, Butler, H. Staying on, and coming off, antidepressants: the experiences of 752 UK adults. Addictive Behaviors 2019;88:82–5.CrossRefGoogle ScholarPubMed
Kato, M, Hori, H, Inoue, T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry 2020;26(1):118–33.Google ScholarPubMed
Reimherr, FW, Strong, RE, Marchant, BK, et al. Factors affecting return of symptoms 1 year after treatment in a 62-week controlled study of fluoxetine in major depression. Journal of Clinical Psychiatry 2001;62(Suppl 2):16–23.Google Scholar
Kanai, T, Takeuchi, H, Furukawa, TA, et al. Time to recurrence after recovery from major depressive episodes and its predictors. Psychological Medicine 2003;33(5):839–45.CrossRefGoogle ScholarPubMed
Ghaziuddin, M, Ghaziuddin, N, Stein, GS. Life events and the recurrence of depression. Canadian Journal of Psychiatry 1990;35(3):239–42.CrossRefGoogle ScholarPubMed
Greden, J. Antidepressant maintenance medications: when to discontinue and how to stop. Journal of Clinical Psychiatry 1993;54(Suppl):46–7.Google ScholarPubMed
Thase, ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectrums 2006;11:12–21.CrossRefGoogle ScholarPubMed
Kessing, L, Andersen, P. Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders. Current Psychiatry Reports 2005;7(6):413–20.CrossRefGoogle ScholarPubMed
Solomon, DA, Keller, MB, Leon, AC, et al. Multiple recurrences of major depressive disorder. American Journal of Psychiatry 2000;157(2):229–33.CrossRefGoogle ScholarPubMed
McGrath, PJ, Stewart, JW, Quitkin, FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. American Journal of Psychiatry 2006;163(9):1542–8.CrossRefGoogle Scholar
Dotoli, D, Spagnolo, C, Bongiorno, F, et al. Relapse during a 6-month continuation treatment with fluvoxamine in an Italian population: the role of clinical, psychosocial and genetic variables. Progress in Neuro-psychopharmacol & Biological Psychiatry 2006;30(3):442–8.CrossRefGoogle Scholar
Ramana, R, Paykel, ES, Cooper, Z, et al. Remission and relapse in major depression: a two-year prospective follow-up study. Psychological Medicine 1995;25(6):1161–70.CrossRefGoogle ScholarPubMed
Kessing, LV. Subtypes of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Psychopathology 2003;36(6):285–91.CrossRefGoogle ScholarPubMed
Flint, AJ, Rifat, SL. Two-year outcome of psychotic depression in late life. American Journal of Psychiatry 1998;155(2):178–83.CrossRefGoogle ScholarPubMed
Dombrovski, AY, Mulsant, BH, Houck, PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of Affective Disorders 2007;103(1–3):77–82.CrossRefGoogle ScholarPubMed
Paykel, ES, Ramana, R, Cooper, Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine 1995;25(6):1171–80.CrossRefGoogle ScholarPubMed
Mueller, TI, Leon, AC, Keller, MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. American Journal of Psychiatry 1999;156(7):1000–6.CrossRefGoogle ScholarPubMed
Kessing, LV. Recurrence in affective disorder: II. Effect of age and gender. British Journal of Psychiatry 1998;172:29–34.CrossRefGoogle ScholarPubMed
Reynolds, CFI, Dew, MA, Pollock, BG, et al. Maintenance treatment of major depression in old age. New England Journal of Medicine 2006;354:1130–8. dx.doi.org/10.1056/NEJMoa052619.CrossRefGoogle ScholarPubMed
Iosifescu, D v., Nierenberg, AA, Alpert, JE, et al. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics 2004;45(5):419–25.CrossRefGoogle ScholarPubMed
Åkerblad, AC, Bengtsson, F, von Knorring, L, et al. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. International Clinical Psychopharmacology 2006;21(2):117–24.CrossRefGoogle ScholarPubMed
Dawson, R, Lavori, PW, Coryell, WH, et al. Maintenance strategies for unipolar depression: an observational study of levels of treatment and recurrence. Journal of Affective Disorders 1998;49(1):31–44.CrossRefGoogle ScholarPubMed
Loonen, AJM, Peer, PGM, Zwanikken, GJ. Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharmaceutisch Weekblad. Scientific Edition 1991;13(4):167–75.CrossRefGoogle ScholarPubMed
Franchini, L, Gasperini, M, Zanardi, R, et al. Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate. Journal of Affective Disorders 2000;58(3):233–6.CrossRefGoogle ScholarPubMed
Reynolds, CF, Perel, JM, Frank, E, et al. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. American Journal of Psychiatry 1999;156(8):1177–81.CrossRefGoogle ScholarPubMed
Frank, E, Kupfer, DJ, Perel, JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. Journal of Affective Disorders 1993;27(3):139–45.CrossRefGoogle ScholarPubMed
Franchini, L, Rossini, D, Bongiorno, F, et al. Will a second prophylactic treatment with a higher dosage of the same antidepressant either prevent or delay new depressive episodes? Psychiatry Research 2000;96:81–5.CrossRefGoogle ScholarPubMed
Pollock, B. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depression and Anxiety 2001;13(1):38–44.Google Scholar
Walters, G, Reynolds, CF, Mulsant, BH, et al. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. Journal of Clinical Psychiatry 1999;60(Suppl 20):21–5.Google ScholarPubMed
Montgomery, SA, Reimitz, PE, Zivkov, M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. International Clinical Psychopharmacology 1998;13(2):63–73.CrossRefGoogle ScholarPubMed
Mulder, R, Hamilton, A, Irwin, L, et al. Treating depression with adjunctive antipsychotics. Bipolar Disorders 2018;20(Suppl 2):17–24.CrossRefGoogle ScholarPubMed
Giakoumatos, CI, Osser, D. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on unipolar nonpsychotic depression. Harvard Review of Psychiatry 2019;27(1):33–52.CrossRefGoogle ScholarPubMed
Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746–58.CrossRefGoogle ScholarPubMed
Sung, SC, Haley, CL, Wisniewski, SR, et al. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. Journal of Clinical Psychiatry 2012;73(7):967–76.Google Scholar
Cooke, MJ, Waring, WS. Citalopram and cardiac toxicity. European Journal of Clinical Pharmacology 2012;69(4):755–60.Google ScholarPubMed
Fava, M, Rush, AJ, Alpert, JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. American Journal of Psychiatry 2008;165(3):342–51.CrossRefGoogle ScholarPubMed
Thase, M, Shelton, R, Khan, A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. Journal of Clinical Psychopharmacology 2006;26(3):250–8.CrossRefGoogle ScholarPubMed
Papakostas, G, Fava, M, Thase, M. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biological Psychiatry 2008;63(7):699–704.CrossRefGoogle ScholarPubMed
Mohamed, S, Johnson, GR, Chen, P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA 2017;318(2):132–45.CrossRefGoogle ScholarPubMed
Pringsheim, T, Gardner, D, Patten, SB. Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? BMJ 2015;350:h569. DOI:10.1136/BMJ.H569.CrossRefGoogle ScholarPubMed
Warden, D, Rush, AJ, Trivedi, MH, et al. The STAR*D Project results: a comprehensive review of findings. Current Psychiatry Reports 2007;9(6):449–59.CrossRefGoogle ScholarPubMed
Amsterdam, JD, Shults, J. MAOI efficacy and safety in advanced stage treatment-resistant depression – a retrospective study. Journal of Affective Disorders 2005;89(1–3):183–8.CrossRefGoogle ScholarPubMed
Gournellis, R, Tournikioti, K, Touloumi, G, et al. Psychotic (delusional) depression and completed suicide: a systematic review and meta-analysis. Annals of General Psychiatry 2018;17:39. DOI:10.1186/S12991-018-0207-1.CrossRefGoogle ScholarPubMed
Petrides, G, Fink, M, Husain, MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. Journal of ECT 2001;17(4):244–53.CrossRefGoogle Scholar
Farahani, A, Correll, CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. Journal of Clinical Psychiatry 2012;73(4):486–96.Google ScholarPubMed
Meyers, BS, Flint, AJ, Rothschild, AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry 2009;66(8):838–47.CrossRefGoogle Scholar
Bruijn, JA, Moleman, P, Mulder, PGH, et al. A double blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacolog 1996;127(3):231–7.CrossRefGoogle ScholarPubMed
van den Broek, WW, Birkenhäger, TK, Mulder, PGH, et al. A double-blind randomized study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology 2004;175:481–6.CrossRefGoogle ScholarPubMed
Kantrowitz, JT, Tampi, RR. Risk of psychosis exacerbation by tricyclic antidepressants in unipolar major depressive disorder with psychotic features. Journal of Affective Disorders 2008;106(3):279–84.CrossRefGoogle ScholarPubMed
Wijkstra, J, Burger, H, van den Broek, WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatrica Scandinavica 2010;121(3):190–200.CrossRefGoogle ScholarPubMed
Price, LH, Charney, DS, Heninger, GR. Variability of response to lithium augmentation in refractory depression. American Journal of Psychiatry 1986;143(11):1387–92.Google ScholarPubMed
Birkenhäger, TK, van den Broek, WW, Wijkstra, J, et al. Treatment of unipolar psychotic depression: an open study of lithium addition in refractory psychotic depression. Journal of Clinical Psychopharmacology 2009;29(5):513–5.CrossRefGoogle ScholarPubMed
Ranjan, R, Meltzer, HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biological Psychiatry 1996;40(4):253–8.CrossRefGoogle ScholarPubMed
Huang, CC, Shiah, IS, Chen, HK, et al. Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression. Clinical Neuropharmacology 2008;31(4):245–7.CrossRefGoogle ScholarPubMed
Łojko, D, Rybakowski, JK. Atypical depression: current perspectives. Neuropsychiatric Disease and Treatment 2017;13:2447–56.CrossRefGoogle ScholarPubMed
Singh, T, Williams, K. Atypical depression. Psychiatry 2006;3(4):33–9.Google ScholarPubMed
Henkel, V, Mergl, R, Allgaier, AK, et al. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Research 2006;141(1):89–101.CrossRefGoogle ScholarPubMed
Papakostas, GI, Nutt, DJ, Hallett, LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biological Psychiatry 2006;60(12):1350–5.CrossRefGoogle ScholarPubMed
Husain, MM, McClintock, SM, Rush, AJ, et al. The efficacy of acute electroconvulsive therapy in atypical depression. Journal of Clinical Psychiatry 2008;69(3):406–11.Google ScholarPubMed
Hedayati, SS, Yalamanchili, V, Finkelstein, FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney International 2012;81(3):247–55.Google Scholar
Mullish, BH, Kabir, MS, Thursz, MR, et al. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacology & Therapeutics 2014;40(8):880–92.Google ScholarPubMed
Briley, M, Moret, C. Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectrums 2008;13(7 Suppl 11):22–6.CrossRefGoogle ScholarPubMed
Spielmans, GI. Duloxetine does not relieve painful physical symptoms in depression: a meta-analysis. Psychotherapy and Psychosomatics 2008;77(1):12–6.CrossRefGoogle Scholar
Bech, P, Gormsen, L, Loldrup, D, et al. The clinical effect of clomipramine in chronic idiopathic pain disorder revisited using the Spielberger State Anxiety Symptom Scale (SSASS) as outcome scale. Journal of Affective Disorders 2009;119(1–3):43–51.CrossRefGoogle ScholarPubMed
Lagerberg, T, Fazel, S, Sjölander, A, et al. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology 2022;47:817–23.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×